Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1

NCT06544733 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT06544733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06544733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1
Lead sponsor
Gilead Sciences
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
August 20, 2024
Completion date
June 30, 2029
Enrollment
675 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection